Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
NUM
Sort by
Title
C
Favorite
A004
Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A004
Cefepime Population Pharmacokinetics Using Volumetric Absorptive Microsampling in Critically Ill Children With Multiple Organ Dysfunction Syndrome
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
015
Characterizing the Covariates & their Impacts on Statistical Evaluations of Clinical Pharmacology Studies in the 351(k) Biologic License Applications
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
033
Clinical Assessment of Mocravimod as a Victim of Drug-Drug Interactions via CYP3A Metabolism & Transporters
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
022
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
130
Clinical Outcomes of Carfilzomib-based Chemotherapy by Relative Dose Intensity in Patients with Relapsed or Refractory Multiple Myeloma
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
065
Clinical Pharmacological Characterization of Cilta-cel, a CAR-T Therapy Directed Against BCMA in Adult Patients With Multiple Myeloma in a Multicohort CARTITUDE-2 Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
019
Clinical Pharmacology Insights into Dosing Strategies of Approved Antibody-Drug Conjugates
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
073
Clinical Pharmacology of Bemarituzumab in Gastric & Gastroesophageal Junction Cancer Patients Supports the Interchangeability of Q2W & Q3W Dosing Regimens
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
091
Clinical Pharmacology of Bispecific T-cell Engagers: A Summary Based on FDA Approvals
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
096
Cluster Analysis to Identify Biomarkers of Treatment Response Following Sirolimus Treatment for HIV Cure
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
156
Comparable Pharmacokinetics of Sacituzumab Govitecan Between Patients With Metastatic Urothelial Cancer & Metastatic Triple-Negative Breast Cancer
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
016
Comparative Pharmacokinetics & Bioequivalence Study of Gatifloxacin 200mg Tablets
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
097
Comparison of Hypoxia Inducible Factor-1A Polymorphisms Between Chronic Kidney Disease Patients & Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
161
Comparison of Nicotine Pharmacokinetic & Subjective Profiles of Three Modern Oral Nicotine Products & a Snus Product
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
A001
Comparison of the Pharmacokinetics/Pharmacodynamics of a Fixed-Dose Combination of Rabeprazole/Magnesium Oxide 20/350 mg to the Enteric-Coated Rabeprazole 20 mg
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
053
Concentration-QTc Analysis of Quemliclustat in Combination With/Without Zimberelimab & nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Cancer
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
092
Concentration-QTc Interim Analysis of I-DXd in Subjects With Advanced Solid Tumors from Study IDeate-Pantumor01 (DS7300-A-J101)
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
098
CYP2B6 & CYP2C19 Phenotypes Influence Sertraline Exposure in Children & Adolescents
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
